Academic Journal
Differences in Posterior Ocular Morphology Following Red Light Therapy Versus 0.01% Atropine for Myopia Control: A Randomized Controlled Trial Analysis.
| Τίτλος: | Differences in Posterior Ocular Morphology Following Red Light Therapy Versus 0.01% Atropine for Myopia Control: A Randomized Controlled Trial Analysis. |
|---|---|
| Συγγραφείς: | Zhao Z; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Wu Y; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Song F; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Li M; Department of Ophthalmology, Shenzhen Nanshan People's Hospital, Shenzhen, People's Republic of China., Wang Y; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Chen R; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Liu Y; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China., Li J; Department of Ophthalmology, Peking University Shenzhen Hospital, Shenzhen, People's Republic of China., He M; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Centre for Eye and Vision Research (CEVR), Hong Kong SAR, People's Republic of China., Chen Y; School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China.; Research Centre for SHARP Vision, The Hong Kong Polytechnic University, Hong Kong SAR, People's Republic of China. |
| Πηγή: | Investigative ophthalmology & visual science [Invest Ophthalmol Vis Sci] 2026 Jul 01; Vol. 67 (8), pp. 35. |
| Τύπος έκδοσης: | Journal Article; Randomized Controlled Trial; Comparative Study; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Association For Research In Vision And Ophthalmology (Arvo) Country of Publication: United States NLM ID: 7703701 Publication Model: Print Cited Medium: Internet ISSN: 1552-5783 (Electronic) Linking ISSN: 01460404 NLM ISO Abbreviation: Invest Ophthalmol Vis Sci Subsets: MEDLINE |
| Imprint Name(s): | Publication: Brookline Ma : Association For Research In Vision And Ophthalmology (Arvo) Original Publication: St. Louis, Mosby. |
| Ιατρικοί όροι (MeSH): | Atropine*/administration & dosage , Myopia*/therapy , Myopia*/drug therapy , Myopia*/diagnosis , Myopia*/physiopathology , Mydriatics*/administration & dosage , Macula Lutea*/pathology , Red Light*, Tomography, Optical Coherence/methods ; Humans ; Child ; Female ; Adolescent ; Male ; Ophthalmic Solutions |
| Περίληψη: | Purpose: The purpose of this study was to compare longitudinal changes in three-dimensional (3D) macular morphology between repeated low-level red-light (RLRL) therapy and 0.01% low-dose atropine (LDA) treatment in myopic children. Methods: This secondary analysis of a randomized controlled trial (RCT) included 50 myopic children (aged 7-15 years) randomized to receive either RLRL therapy (650 ± 10 nm) or 0.01% atropine eye drops. Spectral-domain optical coherence tomography (OCT) was performed at baseline and 1, 3, 6, and 12 months. Custom software was used to perform distortion correction and quantify macular curvature (MC; mm-1), macular outward scleral height (MOSH; µm), and their respective asymmetry indices. Primary outcomes were 12-month changes in average regional macular curvature. Secondary outcomes included changes in MOSH, asymmetry indices, and retinal layer thicknesses. Linear mixed-effects models analyzed longitudinal changes. Results: At 12 months, RLRL showed greater macular flattening than 0.01% atropine across all regions (mean differences, × 10-3 mm-1): central (9.0, 95% confidence interval [CI] = 4.4-13.6, P < 0.01), temporal (9.7, 95% CI = 6.7-12.8, P < 0.001), inferior (8.4, 95% CI = 5.2-11.6, P < 0.001), superior (7.0, 95% CI = 4.0-9.9, P < 0.001), and nasal (3.7, 95% CI = 0.8-6.7, P < 0.05). The inter-group difference was most pronounced centrally and decreased with eccentricity. MOSH decreased superiorly and increased inferiorly in the RLRL group at 12 months, whereas the LDA group showed minimal change. Both nasal-temporal and superior-inferior macular curvature asymmetry indices increased significantly more in the RLRL group (P < 0.001 and P < 0.05, respectively). No inter-group differences in retinal layer thickness changes were observed. Conclusions: Over 12 months, RLRL showed broader macular flattening and more region-specific MOSH changes compared with 0.01% atropine in this cohort. However, the underlying mechanisms and the independent contribution of myopic progression to these morphological differences require further study. |
| Σχόλια: | Erratum in: Invest Ophthalmol Vis Sci. 2026 Aug 3;67(10):25. doi: 10.1167/iovs.67.10.25.. (PMID: 42573186) |
| References: | IEEE J Sel Top Quantum Electron. 2016 May-Jun;22(3):. (PMID: 28070154) Adv Ophthalmol Pract Res. 2025 Apr 15;5(3):157-164. (PMID: 40530375) Photodiagnosis Photodyn Ther. 2025 Aug;54:104651. (PMID: 40449858) Transl Vis Sci Technol. 2024 Oct 1;13(10):29. (PMID: 39432402) Front Pharmacol. 2024 Oct 21;15:1440180. (PMID: 39498339) Sci Rep. 2018 Mar 15;8(1):4594. (PMID: 29545631) Acta Ophthalmol. 2023 Mar;101(2):e167-e176. (PMID: 36004558) J Clin Med. 2023 Feb 07;12(4):. (PMID: 36835853) Invest Ophthalmol Vis Sci. 2020 Dec 1;61(14):15. (PMID: 33320168) Invest Ophthalmol Vis Sci. 2025 Jul 1;66(9):37. (PMID: 40657971) Transl Vis Sci Technol. 2025 Apr 1;14(4):22. (PMID: 40266603) Acta Ophthalmol. 2025 Dec;103(8):1041-1048. (PMID: 40709610) Invest Ophthalmol Vis Sci. 2022 Aug 2;63(9):28. (PMID: 36006653) Sci Rep. 2023 Feb 27;13(1):3321. (PMID: 36849626) Br J Ophthalmol. 2025 Mar 20;109(4):470-475. (PMID: 39244223) Int J Med Sci. 2023 Sep 4;20(10):1363-1376. (PMID: 37786442) Invest Ophthalmol Vis Sci. 2024 May 1;65(5):25. (PMID: 38758640) Transl Vis Sci Technol. 2022 Oct 3;11(10):33. (PMID: 36269184) Am J Ophthalmol. 2025 Feb;270:203-215. (PMID: 39424029) Bull World Health Organ. 2012 Oct 1;90(10):728-38. (PMID: 23109740) Ophthalmology. 2023 Mar;130(3):286-296. (PMID: 36240954) Jpn J Ophthalmol. 2025 Jan;69(1):24-31. (PMID: 39487872) BMB Rep. 2023 Sep;56(9):502-507. (PMID: 37254570) Lancet Reg Health West Pac. 2025 Jun 11;59:101577. (PMID: 40568343) Clin Ophthalmol. 2024 Jan 22;18:215-225. (PMID: 38283180) Ophthalmol Ther. 2024 Jul;13(7):1909-1924. (PMID: 38743158) Transl Vis Sci Technol. 2024 Oct 1;13(10):41. (PMID: 39476086) J Clin Med. 2022 Mar 14;11(6):. (PMID: 35329923) Transl Vis Sci Technol. 2022 Jul 8;11(7):24. (PMID: 35895054) Eye (Lond). 2013 Mar;27(3):410-7. (PMID: 23306730) Ophthalmol Ther. 2023 Apr;12(2):1223-1237. (PMID: 36790672) Community Eye Health. 2019;32(105):5-6. (PMID: 31409941) J Clin Med. 2022 Dec 17;11(24):. (PMID: 36556114) Eye (Lond). 2024 Apr;38(5):923-929. (PMID: 37898715) Am J Ophthalmol. 2022 May;237:130-138. (PMID: 34942105) Invest Ophthalmol Vis Sci. 2018 Nov 1;59(13):5455-5461. (PMID: 30452599) |
| Substance Nomenclature: | 7C0697DR9I (Atropine) 0 (Mydriatics) 0 (Ophthalmic Solutions) |
| Entry Date(s): | Date Created: 20260714 Date Completed: 20260714 Latest Revision: 20260922 |
| Update Code: | 20260922 |
| PubMed Central ID: | PMC13387244 |
| DOI: | 10.1167/iovs.67.8.35 |
| PMID: | 42446481 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!